Miller-Fisher Syndrome and Guillain-Barre Syndrome overlap syndrome in a patient post Oxford-AstraZeneca SARS-CoV-2 vaccination.
BMJ Case Rep
; 14(11)2021 Nov 30.
Article
in English
| MEDLINE | ID: covidwho-1546480
ABSTRACT
We describe a patient who developed bilateral oculomotor nerve palsy, ataxia, facial diplegia and lower limb weakness 2 weeks post-Oxford-AstraZeneca SARS-CoV2 vaccination, consistent with Miller-Fisher syndrome (MFS) and Guillain-Barre syndrome (GBS) overlap syndrome. Although some features of the patient's presentation were typical of recently reported cases of a rare GBS variant post-Oxford-AstraZeneca vaccination, including severe facial weakness and a lack of respiratory involvement, to our knowledge this is the first reported case of MFS associated with SARS-CoV2 vaccination. While postvaccination GBS remains rare, it appears to have a favourable prognosis, and recognising this entity is therefore important for patient counselling and monitoring for potential complications.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Miller Fisher Syndrome
/
Guillain-Barre Syndrome
/
COVID-19
Type of study:
Case report
/
Diagnostic study
/
Prognostic study
Topics:
Vaccines
/
Variants
Limits:
Humans
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Bcr-2021-246701
Similar
MEDLINE
...
LILACS
LIS